Dr. Martin Hager, MBA

oncology cancer personalized healthcare targeted therapy big data in oncology precision medicine personalized medicine ntrk inhibitor ds-6051 dr. martin h. hager treatment comprehensive genomic profiling artificial intelligence therapy venture capital clinical trial metastasis tumor cancer patients personalised digital health interventions eprom rwd kaiku health tecentriq digitale gesundheitsanwendung diga digital patient monitoring and management decision support pathology mtb cup-syndrom clinical study cupisco cup molecular tumor board clinical decision support cancer of unknown primary tumor-agnostic pan-tumor astrazeneca taletrectinib ros1 inhibitor pharmaceutical daiichi-sankyo co. ltd. digital frankfurter allgemeine zeitung strategy digital pathology digital strategy big data platform diagnostic diagnostics healthcare oncology pipeline genome sequencing profile flatiron foundation medicine phc 2.0 phc mba practicum finance germany fundraising history of capital markets global japan stock market economy investment capital markets usa seed financing globalization debt financing fund performance industry entrepreneurship mba pharmaceuticals big pharma fostering leaders leadership angiogenesis martin h. hager department of defense biomarker prognostic innovation angel investor peter hirth arqule nsclc non-small cell lung cancer daiichi sankyo kinase inhibitor mesenchymal amoeboid transition amoeboid emt migration epithelial mesenchymal transition drf3 formin plasticity vemurafenib plexxikon ros1/ntrk inhibitor dr. hager daiichi-sankyo daiichi sankyo co. ltd. inhibitor ntrk translocation ros1